- Country: United States
Latest coverage
- Country: Cyprus
Vaxcyte prices $1 billion dual offering of stock and notes
- Press releases
- Country: United States
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
SAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings of 7,412,500 shares of common stock, pre-funded warrants to purchase 400,000 shares of common…
- Country: United States
Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers
Biotech stocks took a hit Tuesday, with Vaxcyte, Moderna and Revolution Medicines posting some of the steepest losses. The post Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers appeared first on Investor's Business Daily .
- Country: Cyprus
Why is Vaxcyte stock sliding in after-hours trading today?
- Country: United States
Vaxcyte files separate $500M offerings for equity/pre-funded warrants and 2032 convertible notes
- Press releases
- Country: United States
Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
SAN CARLOS, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced underwritten public offerings of $500 million of its common stock and pre-funded warrants and $500 million aggregate principal…
- Country: Cyprus
BTIG reiterates Vaxcyte stock rating on strong VAX-31 trial data
- Country: United States
STAT+: Pharmalittle: We’re reading about a Vaxcyte pneumococcal shot, increasing pharma M&A, and more
Vaxcyte disclosed that its pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up a competition with Pfizer and Merck
- Country: United States
STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market
Vaxcyte said its experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up the biotech to compete with Pfizer and Merck.